Rebecca C Fitzgerald
Overview
Explore the profile of Rebecca C Fitzgerald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
265
Citations
8589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Honing J, Tan W, Lu V, Gourgiotis V, Gianfrancesco I, Schumacher A, et al.
United European Gastroenterol J
. 2025 Feb;
PMID: 39949075
Introduction: Specialist guidelines recommend endoscopic surveillance for Barrett's esophagus to reduce mortality related to esophageal adenocarcinoma, but the setting for optimal Barrett's esophagus monitoring is unclear. We assessed progression rate...
2.
3.
Gourgiotis V, Graham C, Foerster K, Fitzgerald R, Harvey R, Morris D
Aliment Pharmacol Ther
. 2025 Jan;
61(5):876-885.
PMID: 39794909
Background: Acid reflux is a common presentation in primary care leading to a high volume of referrals to endoscopy that are often normal. Aims: To determine whether a non-endoscopic capsule...
4.
Ganguli P, Basanta C, Acha-Sagredo A, Misetic H, Armero M, Mendez A, et al.
Nat Cancer
. 2025 Jan;
6(1):158-174.
PMID: 39753721
CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution...
5.
Stevenson L, Cairns L, Li X, Jammula S, Taylor H, Douglas R, et al.
Sci Rep
. 2024 Dec;
14(1):32121.
PMID: 39739112
The incidence of oesophageal adenocarcinoma (OAC) has risen six-fold in western countries over the last forty years but survival rates have only marginally improved. Hyperactivation of the PI3K-AKT-mTOR pathway is...
6.
Carmona J, Chavarria E, Donoghue K, von Gertten C, Oberrauch P, Pailler E, et al.
Cancer Discov
. 2024 Jun;
14(7):1147-1153.
PMID: 38870393
Cancer Core Europe brings together the expertise, resources, and interests of seven leading cancer institutes committed to leveraging collective innovation and collaboration in precision oncology. Through targeted efforts addressing key...
7.
Ng A, McClurg D, Wesley B, Zamani S, Black E, Miremadi A, et al.
Nat Commun
. 2024 May;
15(1):4533.
PMID: 38806493
No abstract available.
8.
Ng A, McClurg D, Wesley B, Zamani S, Black E, Miremadi A, et al.
Nat Commun
. 2024 May;
15(1):4074.
PMID: 38744814
Esophageal adenocarcinoma is a prominent example of cancer characterized by frequent amplifications in oncogenes. However, the mechanisms leading to amplicons that involve breakage-fusion-bridge cycles and extrachromosomal DNA are poorly understood....
9.
Tan W, Maroni R, Offman J, Zamani S, Sasieni P, Fitzgerald R
Gastroenterology
. 2024 May;
167(4):798-800.e4.
PMID: 38718951
No abstract available.
10.
Neilson L, Fitzgerald R, Deane J, Debiram-Beecham I, Gulle H, Rees C, et al.
Frontline Gastroenterol
. 2024 Mar;
15(1):28-34.
PMID: 38487563
Objective: Cytosponge is a novel technology for oesophageal pathology diagnosis. Uses include diagnosis of Barrett's oesophagus and as a triage tool to prioritise upper gastrointestinal endoscopy. Patient experience is a...